12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

UK-279,276 (rNIF): Began Phase IIb trial

Corvas International Inc. (CVAS), San Diego, Calif.
Product: UK-279,276 (rNIF)
Business: Neurological
Therapeutic category: Immunosuppression
Target: CD11/CD18...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >